EN
ENSCW
Ensysce Biosciences, Inc.
No data for this timeframe.
Vol
Market Cap$3.9M
Cap SizeNano Cap
SEC Reports5
Recent Activity
Jun 4, 2026
SEC
Ensysce Biosciences filed an S-3 registration statement to register 1,300,000 shares of common stock for resale by selli
S-3 — Impact 6/10
May 22, 2026
SEC
Ensysce Biosciences received a Nasdaq delisting notice on May 21, 2026 for failing to meet the $2.5M stockholders' equit
8-K — Impact 7/10
May 15, 2026
SEC
Ensysce Biosciences reported Q1 2026 results with a net loss of $3.6M, widening from a $1.9M loss in Q1 2025, driven by
8-K — Impact 7/10
Latest Reports
BEARISH
S-3
6/10
Ensysce Biosciences filed an S-3 registration statement to register 1,300,000 shares of common stock for resale by selli
Jun 4, 2026
BEARISH
8-K
7/10
Ensysce Biosciences received a Nasdaq delisting notice on May 21, 2026 for failing to meet the $2.5M stockholders' equit
May 22, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.4/10.
BEARISH
S-3
6/10
Ensysce Biosciences filed an S-3 registration statement to register 1,300,000 shares of common stock
Jun 4, 2026
BEARISH
8-K
7/10
Ensysce Biosciences received a Nasdaq delisting notice on May 21, 2026 for failing to meet the $2.5M
May 22, 2026
BEARISH
8-K
7/10
Ensysce Biosciences reported Q1 2026 results with a net loss of $3.6M, widening from a $1.9M loss in
May 15, 2026
NEUTRAL
8-K
4/10
Ensysce Biosciences reported fourth quarter and full-year 2025 financial results, showing a narrower
Apr 21, 2026
NEUTRAL
8-K
3/10
Ensysce Biosciences, Inc. announced the resignation of board member Dr. Curtis Rosebraugh, effective
Apr 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 38.5% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 285.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 34.2% | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.